US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

37.31

-0.1119-0.30%

Post-market: 37.600.2856+0.77%16:10 EDT

Volume:2K

Turnover:64.61K

Market Cap:7.46M

PE:- -

High:37.75

Open:37.31

Low:37.31

Close:37.43

52wk High:43.01

52wk Low:25.42

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.12

T/O Rate:0.86%

Dividend:0.32

Dividend Rate:0.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26

Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million

Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million

THOMSON REUTERS

Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029

THOMSON REUTERS

Xenon Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

The Race to Come up with the Next Big Sleep Drug

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Scholar Rock Holding Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028

Scholar Rock Files for up to $200 Million At-the-Market Stock Offering

Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Praxis Precision Net Loss Widens 17.7% to $83.72 Million in Q2 FY26

Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate

Benzinga Earnings

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

THOMSON REUTERS

Praxis Precision Q2 EPS USD -2.87

THOMSON REUTERS

Praxis Precision Q2 Operating Expenses USD 96.904 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/IBRN/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":37.3143,"timestamp":1789416000000,"preClose":37.4262,"halted":0,"volume":1718,"hourTrading":{"tag":"盘后","latestPrice":37.5999,"preClose":37.3143,"latestTime":"16:10 EDT","volume":8,"amount":298.4058,"timestamp":1789416603823,"change":0.2856,"changeRate":0.007654,"amplitude":0},"delay":0,"changeRate":-0.0029898840918928062,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.1119,"latestTime":"09-14 16:00:00 EDT","open":37.31,"high":37.745,"low":37.31,"amount":64609,"amplitude":0.011623,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":37.4262,"sharesOutstanding":150000,"nav":37.384466,"aum":7476893.2,"dividendRate":0.008603,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.5999,"preClose":37.3143,"latestTime":"16:10 EDT","volume":8,"amount":298.4058,"timestamp":1789416603823,"change":0.2856,"changeRate":0.007654,"amplitude":0},"volumeRatio":1.116309,"impliedVol":0.1627,"impliedVolPercentile":0.856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.116309,"shares":200000,"dividePrice":0.321,"high":37.745,"amplitude":0.011623,"preClose":37.4262,"low":37.31,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":37.3143,"eps":0,"divideRate":0.008603,"volume":1718,"delay":0,"ttmEps":0,"open":37.31,"prevYearClose":32.3193,"prevWeekClose":37.4262,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":39.0596,"twentyDayClose":39.1355,"sixtyDayClose":35.5221},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657650957","title":"Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650957","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650957?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047436,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q2 net loss widens on higher warrant costsOverviewUS biopharma firm's Q2 net loss widens, driven by higher warrant liabilities and expensesCompany raised $805 mln in public offer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009355771.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","DFTX","PRAX","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IBRN","LU0109394709.USD","DTIL","LU0889565916.HKD","VTVT","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4007","LU2065171402.SGD","NBIX","BK4563","LU0154245673.USD","LU0109394709.USD","LU0320765992.SGD","LU2065169927.USD","IBRN","LU0889565916.HKD","IMRX","PSIL","LU2065171311.SGD","GHRS","IE00BFTCPJ56.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","BK4539","IE00B4R5TH58.HKD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","PRAX","LU0823416689.USD","LU2065170008.USD","IE0002141913.USD","LU0154245756.USD","IE00BJT1NW94.SGD","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571056","title":"Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:07","pubTimestamp":1786046831,"startTime":"0","endTime":"0","summary":"Xenon net loss widens 30.7% to $110.74 million in Q2 FY26Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.R&D costs rose to USD 99.2 million from USD 75 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbgCR29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","XENE","BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","NDAQ","BK4588","IE00BKPKM429.USD","LU2095319765.USD","SBIO","SG9999014013.SGD","IBRN","IE00B3QW5Z07.USD","LU0314104364.USD","BCDF","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365271","title":"Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365271?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 MillionAug 06 (Reuters) - Xenon Pharmaceuticals Q2 income from operations USD -123.155 million.Q2 operating expenses USD 123.155 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652480","title":"Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652480?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521606","title":"Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521606?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465223","title":"Xenon Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465223?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA4YCGCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SBIO","IBRN","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999018857.SGD","LU0097036916.USD","LU0106261372.USD","LU0353189680.USD","LU2552382058.USD","SG9999014906.USD","BK4599","LU1064131342.USD","LU0820562030.AUD","LU1145028129.USD","LU2746668974.SGD","SG9999001176.SGD","IYH","LU0882574055.USD","LU0385154629.USD","LU2361045086.USD","LU1814569148.SGD","LU1551013342.USD","LU0058720904.USD","LU0266013472.USD","SG9999014914.USD","LU1979441026.SGD","SG9999017495.SGD","LU0466842654.USD","LU2108987350.USD","LU2168564065.EUR","LU0417517546.SGD","IE00BJT1NW94.SGD","LU0133085943.USD","FTXH","LU1989771016.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","FHLC","ILDR","LU2461242641.AUD","ELIS","LU2023251221.USD","LU2324357040.USD","LU0079474960.USD","LU2028103732.USD","LU1629891620.HKD","LU0323591593.USD","IE0004445239.USD","SG9999014898.SGD","LU1061106388.HKD","LU1988902786.USD","IE00BJLML261.HKD","SGXZ57979304.SGD","LU0225283273.USD","LU2471134523.USD","LU2471134952.CNY","LU0882574139.USD","IE00B1BXHZ80.USD","LU1323610961.USD","LU0640476718.USD","PPH","LU1127390331.HKD","OZEM","GDOC","LLII","LU0203202063.USD","MEDX","LU0210536198.USD","LU0320765992.SGD","LU2236285917.USD","IE00BFSS7M15.SGD","LU2087625088.SGD","LU2063271972.USD","LU2111349929.HKD","IE00BKPKM429.USD","LU1093756168.USD","IE00BK4W5L77.USD","LU2168564149.EUR","LU2750360997.AUD","PSIL","LU0198837287.USD","LU0689472784.USD","LU0320765059.SGD","LU0786609619.USD","LU2471134879.HKD","LU2468319806.SGD","LU1551013425.SGD","HRTS","LU2360106947.USD","LU2552382132.HKD","IXJ","LU0708995401.HKD","IE00BN29S564.USD","LU2237443895.HKD","LU2471134796.USD","MEDI","SGXZ99366536.SGD","IE00BKDWB100.SGD","LU0174119429.USD","LU0820561909.HKD","LU2237443465.HKD","LU2602419157.SGD","LU0061475181.USD","IBRN","LU2106854487.HKD","IE00B2B36J28.USD","LU2491050154.USD","LU1280957306.USD","IE00BFSS8Q28.SGD","LU2750360641.GBP","TRUH","LU0316494557.USD","LU0456855351.SGD","LU1291159041.SGD","PJP","LU0122379950.USD","LU0256863902.USD","IE00BK4W5M84.HKD","LU1267930730.SGD","LU0345770308.USD","LU0158827781.USD","LU0471298694.HKD","CURE","SG9999018865.SGD","LU2756315318.SGD","IE00B4R5TH58.HKD","LU1069344957.HKD","LU2756315664.SGD","LU2237438978.USD","TMED","IE00B4JS1V06.HKD","BK4007","IE0002141913.USD","THNR","AGNG","LU0354030438.USD","LU1983299246.USD","LU0353189763.USD","LU2491050071.SGD","LU0432979614.USD","LU1720051017.SGD","LU2271345857.HKD","LU2491049909.HKD","MHIP","CANC","LU0823434583.USD","LU0787776722.HKD","JDOC","LU1623119135.USD","IE00B7KXQ091.USD","LU2168564222.USD","SG9999015986.USD","SGXZ51526630.SGD","XLV","IE00BJJMRX11.SGD","IHE","PSCH","LU0109391861.USD","LU2237443549.SGD","LU2462157665.USD","SG9999001176.USD","BK4581","RXL","LU2456880835.USD","LU2089984988.USD","LU2417539215.USD","LU0238689110.USD","LU1057294990.SGD","LU2361044865.SGD","SGXZ81514606.USD","LU0471298777.SGD","LU2264538146.SGD","LU0094547139.USD","LU2552382215.SGD","LU0109394709.USD","LU2168564495.EUR","IE00B775H168.HKD","LU0256863811.USD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU0823434740.USD","SG9999015952.SGD","VHT","LU1548497426.USD","LU0889565916.HKD","BK4585","LU0683600562.USD","LU1035775433.USD","LU1868836591.USD","LU0345770993.USD","BK4588","SG9999014880.SGD","BK4533","LLY","LU2211815571.USD","LU2237443978.SGD","SGXZ31699556.SGD","BK4139","LU2213496289.HKD","SG9999013999.USD","LU2361044949.HKD","LU2237443382.USD","BK4516","IE0009355771.USD","LU2896262040.SGD","IE00BWXC8680.SGD","LU0354030511.USD","LU0943347566.SGD","LU1917777945.USD","ALKS","LU0096364046.USD","LU2746668461.USD","WDNA","LU0964807845.USD","LU1804176565.USD","LU2265009873.SGD","LU2168563687.JPY","IE00BJJMRY28.SGD","LU2462591350.SGD","LU1868836757.USD","LU1974910355.USD","SG9999015978.USD","LU0289739699.SGD","LU0006306889.USD","TAK","BK4534","LLYZ","LU2089284900.SGD","LU0234572021.USD","IE00B1XK9C88.USD","LLYX","LU2237443622.USD","GB00BDT5M118.USD","IE0001KFT4U8.USD","IE0005OL40V9.USD","LU0114720955.EUR","LU0672654240.SGD","LU1023059063.AUD","LU1712237335.SGD","LU2357305700.SGD","LU2023250330.USD","LU2112291526.USD","LU1232071149.USD","LU0158827948.USD","LU0203201768.USD","FBT","SG9999015945.SGD","ELIL","IE0004445015.USD","LU1868837136.USD","LU1868837300.USD","LU1720051108.HKD","LU2023250504.SGD","LU0820561818.USD","LU1366192091.USD","LU1868836914.USD","LU2089283258.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651400","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651400?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:50","pubTimestamp":1786038610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Privia Health Group (PRV...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE0009355771.USD","PRAX","XLV","LU0889565916.HKD","LU0029874061.USD","XBI","IE00BJT1NW94.SGD","LU0128526141.USD","PRVA","BK4581","BK4539","IE00B4R5TH58.HKD","BK4588","IE00BJJMRZ35.SGD","HCSG","IBRN","LABU","TNYA","IE0002141913.USD","BK4585","IE00BFTCPJ56.SGD","BK4196","IE00B2B36J28.USD","BK4137","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163708","title":"Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163708","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163708?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:07","pubTimestamp":1786025274,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings SummaryPraxis Precision Medicines, Inc.PRAX.OQreported a quarterly adjusted loss of $2.87 per share for the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44326M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0320765992.SGD","IBRN","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657321716","title":"Scholar Rock Holding Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657321716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657321716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:31","pubTimestamp":1786023115,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation reports results for the quarter ended June 30 - Earnings SummaryScholar Rock Holding CorporationSRRK.OQreported a quarterly adjusted loss of 84 cents per share for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657111634","title":"Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657111634","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657111634?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:53","pubTimestamp":1786020784,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines’ Q2 2026 results showed a net loss of $83.7 million, up from $71.1 million a year earlier, while diluted loss per share narrowed to $2.87 from $3.31 because the weighted-average share count increased. R&D expense rose to $69.4 million and G&A expense more than doubled to $27.5 million. Cash, cash equivalents and marketable securities totaled approximately $1.4 billion at June 30, supporting operations into 2028 as Praxis prepares for regulatory decisions on relutrigine and ulixacaltamide and advances key epilepsy studies.","market":"sh","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262084149-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","LU0889565916.HKD","IE00B2B36J28.USD","PRAX","BK4588","LABU","IE00BJJMRZ35.SGD","BK4139","LU0320765992.SGD","IE00BFTCPJ56.SGD","IBRN","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863176","title":"Scholar Rock Files for up to $200 Million At-the-Market Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863176","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863176?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:50","pubTimestamp":1786020621,"startTime":"0","endTime":"0","summary":"Scholar Rock files for up to $200 million at-the-market stock offeringScholar Rock launched a refreshed at-the-market equity program to sell up to USD 200 million of common stock through Jefferies.The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLMYqCd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696631","title":"Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657696631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:37","pubTimestamp":1786019853,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA datesPraxis Precision Medicines highlighted four late-stage CNS programs, citing portfolio peak sale","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9lM7CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IBRN","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","PRAX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","PRAX","IE00BJT1NW94.SGD","BK4139","HRMY","IE0002141913.USD","IE0009355771.USD","PSIL","GHRS","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","VNDA","LU0109394709.USD","BK4007","LU0889565916.HKD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657398376","title":"Praxis Precision Net Loss Widens 17.7% to $83.72 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657398376","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657398376?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:08","pubTimestamp":1786018121,"startTime":"0","endTime":"0","summary":"Praxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26Praxis Precision Medicines posted a Q2 GAAP net loss of USD 83.7 million, widening from USD 71.1 million a year earlier.R&D expenses rose 10.16% to USD 69.4 million, driven by higher Solidus spending and personnel costs, partly offset by lower Cerebrum expenses.G&A costs more than doubled to USD 27.5 million, on higher professional fees and personnel-related expenses.Cash, cash equivalents and marketable securities totaled USD 1.4 billion at June 30, extending the expected operating runway into 2028.FDA mid-cycle reviews flagged no major safety or efficacy issues for ulixacaltamide  or relutrigine .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicine","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9blbZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0320765992.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IBRN","BK4139","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636437","title":"Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636437","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636437?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:03","pubTimestamp":1786017826,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over losses of $(3.31) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60991365/praxis-precision-medicine-q2-eps-2-87-beats-3-65-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IBRN","IE0002141913.USD","IE0009355771.USD","BK4139","LU0320765992.SGD","LU0109394709.USD","PRAX","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863669","title":"Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863669?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUAB8QH5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRAX","IE0002141913.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009355771.USD","IBRN","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636569","title":"Praxis Precision Q2 EPS USD -2.87","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636569?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX4G8G05:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","PRAX","BK4139","IBRN","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657366906","title":"Praxis Precision Q2 Operating Expenses USD 96.904 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657366906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657366906?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX4G8G05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","PRAX","BK4139","IBRN","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}